Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?
- 20 September 2021
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 32 (11), 1311-1313
- https://doi.org/10.1016/j.annonc.2021.09.010
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune CheckpointFrontiers in Immunology, 2020
- Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated resultsAnnals of Oncology, 2019
- LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapyNature Communications, 2019
- Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoringNature, 2019
- Transforming Growth Factor-β Signaling in Immunity and CancerImmunity, 2019
- Cancer Inflammation and CytokinesCold Spring Harbor Perspectives in Biology, 2017
- Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patientsAnnals of Oncology, 2017
- Leukemia inhibitory factor (LIF)Cytokine & Growth Factor Reviews, 2015
- Liquid biopsy: monitoring cancer-genetics in the bloodNature Reviews Clinical Oncology, 2013
- Tumour necrosis factor and cancerNature Reviews Cancer, 2009